Circulating suPAR in two cohorts of primary FSGS

Changli Wei, Howard Trachtman, Jing Li, Chuanhui Dong, Aaron L. Friedman, Jennifer J. Gassman, June L. McMahan, Milena Radeva, Karsten M. Heil, Agnes Trautmann, Ali Anarat, Sevinc Emre, Gian M. Ghiggeri, Fatih Ozaltin, Dieter Haffner, Debbie S. Gipson, Frederick J. Kaskel, Dagmar Christiane Fischer, Franz Schaefer, Jochen Reiser

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to primary FSGS, and one recent study demonstrated elevated levels of serum suPAR in patients with the disease. Here, we analyzed circulating suPAR levels in two cohorts of children and adults with biopsy-proven primary FSGS: 70 patients from the North America-based FSGS clinical trial (CT) and 94 patients from PodoNet, the Europe-based consortium studying steroid-resistant nephrotic syndrome. Circulating suPAR levels were elevated in 84.3% and 55.3% of patients with FSGS patients in the CT and PodoNet cohorts, respectively, compared with 6% of controls (P<0.0001); inflammation did not account for this difference. Multiple regression analysis suggested that lower suPAR levels associated with higher estimated GFR, male sex, and treatment with mycophenolate mofetil. In the CT cohort, there was a positive association between the relative reduction of suPAR after 26 weeks of treatment and reduction of proteinuria, with higher odds for complete remission (P=0.04). In the PodoNet cohort, patients with an NPHS2 mutation had higher suPAR levels than those without a mutation. In conclusion, suPAR levels are elevated in geographically and ethnically diverse patients with FSGS and do not reflect a nonspecific proinflammatory milieu. The associations between a change in circulating suPAR with different therapeutic regimens and with remission support the role of suPAR in the pathogenesis of FSGS.

Original languageEnglish (US)
Pages (from-to)2051-2059
Number of pages9
JournalJournal of the American Society of Nephrology
Volume23
Issue number12
DOIs
StatePublished - 2012

Fingerprint

Clinical Trials
Mycophenolic Acid
Mutation
Urokinase-Type Plasminogen Activator
Nephrotic Syndrome
North America
Proteinuria
Therapeutics
Animal Models
Steroids
Regression Analysis
Pathology
Inflammation
Biopsy
Serum

ASJC Scopus subject areas

  • Nephrology

Cite this

Wei, C., Trachtman, H., Li, J., Dong, C., Friedman, A. L., Gassman, J. J., ... Reiser, J. (2012). Circulating suPAR in two cohorts of primary FSGS. Journal of the American Society of Nephrology, 23(12), 2051-2059. https://doi.org/10.1681/ASN.2012030302

Circulating suPAR in two cohorts of primary FSGS. / Wei, Changli; Trachtman, Howard; Li, Jing; Dong, Chuanhui; Friedman, Aaron L.; Gassman, Jennifer J.; McMahan, June L.; Radeva, Milena; Heil, Karsten M.; Trautmann, Agnes; Anarat, Ali; Emre, Sevinc; Ghiggeri, Gian M.; Ozaltin, Fatih; Haffner, Dieter; Gipson, Debbie S.; Kaskel, Frederick J.; Fischer, Dagmar Christiane; Schaefer, Franz; Reiser, Jochen.

In: Journal of the American Society of Nephrology, Vol. 23, No. 12, 2012, p. 2051-2059.

Research output: Contribution to journalArticle

Wei, C, Trachtman, H, Li, J, Dong, C, Friedman, AL, Gassman, JJ, McMahan, JL, Radeva, M, Heil, KM, Trautmann, A, Anarat, A, Emre, S, Ghiggeri, GM, Ozaltin, F, Haffner, D, Gipson, DS, Kaskel, FJ, Fischer, DC, Schaefer, F & Reiser, J 2012, 'Circulating suPAR in two cohorts of primary FSGS', Journal of the American Society of Nephrology, vol. 23, no. 12, pp. 2051-2059. https://doi.org/10.1681/ASN.2012030302
Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ et al. Circulating suPAR in two cohorts of primary FSGS. Journal of the American Society of Nephrology. 2012;23(12):2051-2059. https://doi.org/10.1681/ASN.2012030302
Wei, Changli ; Trachtman, Howard ; Li, Jing ; Dong, Chuanhui ; Friedman, Aaron L. ; Gassman, Jennifer J. ; McMahan, June L. ; Radeva, Milena ; Heil, Karsten M. ; Trautmann, Agnes ; Anarat, Ali ; Emre, Sevinc ; Ghiggeri, Gian M. ; Ozaltin, Fatih ; Haffner, Dieter ; Gipson, Debbie S. ; Kaskel, Frederick J. ; Fischer, Dagmar Christiane ; Schaefer, Franz ; Reiser, Jochen. / Circulating suPAR in two cohorts of primary FSGS. In: Journal of the American Society of Nephrology. 2012 ; Vol. 23, No. 12. pp. 2051-2059.
@article{dd49b4e362cd466fae8bf2b2516ff682,
title = "Circulating suPAR in two cohorts of primary FSGS",
abstract = "Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to primary FSGS, and one recent study demonstrated elevated levels of serum suPAR in patients with the disease. Here, we analyzed circulating suPAR levels in two cohorts of children and adults with biopsy-proven primary FSGS: 70 patients from the North America-based FSGS clinical trial (CT) and 94 patients from PodoNet, the Europe-based consortium studying steroid-resistant nephrotic syndrome. Circulating suPAR levels were elevated in 84.3{\%} and 55.3{\%} of patients with FSGS patients in the CT and PodoNet cohorts, respectively, compared with 6{\%} of controls (P<0.0001); inflammation did not account for this difference. Multiple regression analysis suggested that lower suPAR levels associated with higher estimated GFR, male sex, and treatment with mycophenolate mofetil. In the CT cohort, there was a positive association between the relative reduction of suPAR after 26 weeks of treatment and reduction of proteinuria, with higher odds for complete remission (P=0.04). In the PodoNet cohort, patients with an NPHS2 mutation had higher suPAR levels than those without a mutation. In conclusion, suPAR levels are elevated in geographically and ethnically diverse patients with FSGS and do not reflect a nonspecific proinflammatory milieu. The associations between a change in circulating suPAR with different therapeutic regimens and with remission support the role of suPAR in the pathogenesis of FSGS.",
author = "Changli Wei and Howard Trachtman and Jing Li and Chuanhui Dong and Friedman, {Aaron L.} and Gassman, {Jennifer J.} and McMahan, {June L.} and Milena Radeva and Heil, {Karsten M.} and Agnes Trautmann and Ali Anarat and Sevinc Emre and Ghiggeri, {Gian M.} and Fatih Ozaltin and Dieter Haffner and Gipson, {Debbie S.} and Kaskel, {Frederick J.} and Fischer, {Dagmar Christiane} and Franz Schaefer and Jochen Reiser",
year = "2012",
doi = "10.1681/ASN.2012030302",
language = "English (US)",
volume = "23",
pages = "2051--2059",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - Circulating suPAR in two cohorts of primary FSGS

AU - Wei, Changli

AU - Trachtman, Howard

AU - Li, Jing

AU - Dong, Chuanhui

AU - Friedman, Aaron L.

AU - Gassman, Jennifer J.

AU - McMahan, June L.

AU - Radeva, Milena

AU - Heil, Karsten M.

AU - Trautmann, Agnes

AU - Anarat, Ali

AU - Emre, Sevinc

AU - Ghiggeri, Gian M.

AU - Ozaltin, Fatih

AU - Haffner, Dieter

AU - Gipson, Debbie S.

AU - Kaskel, Frederick J.

AU - Fischer, Dagmar Christiane

AU - Schaefer, Franz

AU - Reiser, Jochen

PY - 2012

Y1 - 2012

N2 - Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to primary FSGS, and one recent study demonstrated elevated levels of serum suPAR in patients with the disease. Here, we analyzed circulating suPAR levels in two cohorts of children and adults with biopsy-proven primary FSGS: 70 patients from the North America-based FSGS clinical trial (CT) and 94 patients from PodoNet, the Europe-based consortium studying steroid-resistant nephrotic syndrome. Circulating suPAR levels were elevated in 84.3% and 55.3% of patients with FSGS patients in the CT and PodoNet cohorts, respectively, compared with 6% of controls (P<0.0001); inflammation did not account for this difference. Multiple regression analysis suggested that lower suPAR levels associated with higher estimated GFR, male sex, and treatment with mycophenolate mofetil. In the CT cohort, there was a positive association between the relative reduction of suPAR after 26 weeks of treatment and reduction of proteinuria, with higher odds for complete remission (P=0.04). In the PodoNet cohort, patients with an NPHS2 mutation had higher suPAR levels than those without a mutation. In conclusion, suPAR levels are elevated in geographically and ethnically diverse patients with FSGS and do not reflect a nonspecific proinflammatory milieu. The associations between a change in circulating suPAR with different therapeutic regimens and with remission support the role of suPAR in the pathogenesis of FSGS.

AB - Overexpression of soluble urokinase receptor (suPAR) causes pathology in animal models similar to primary FSGS, and one recent study demonstrated elevated levels of serum suPAR in patients with the disease. Here, we analyzed circulating suPAR levels in two cohorts of children and adults with biopsy-proven primary FSGS: 70 patients from the North America-based FSGS clinical trial (CT) and 94 patients from PodoNet, the Europe-based consortium studying steroid-resistant nephrotic syndrome. Circulating suPAR levels were elevated in 84.3% and 55.3% of patients with FSGS patients in the CT and PodoNet cohorts, respectively, compared with 6% of controls (P<0.0001); inflammation did not account for this difference. Multiple regression analysis suggested that lower suPAR levels associated with higher estimated GFR, male sex, and treatment with mycophenolate mofetil. In the CT cohort, there was a positive association between the relative reduction of suPAR after 26 weeks of treatment and reduction of proteinuria, with higher odds for complete remission (P=0.04). In the PodoNet cohort, patients with an NPHS2 mutation had higher suPAR levels than those without a mutation. In conclusion, suPAR levels are elevated in geographically and ethnically diverse patients with FSGS and do not reflect a nonspecific proinflammatory milieu. The associations between a change in circulating suPAR with different therapeutic regimens and with remission support the role of suPAR in the pathogenesis of FSGS.

UR - http://www.scopus.com/inward/record.url?scp=84870546490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870546490&partnerID=8YFLogxK

U2 - 10.1681/ASN.2012030302

DO - 10.1681/ASN.2012030302

M3 - Article

VL - 23

SP - 2051

EP - 2059

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 12

ER -